Ranibizumab is an antibody fragment without the Fc portion and affinity-matured to more strongly bind VEGF-A.
The humanized anti-VEGF-A monoclonal antibody drug Bevacizumab (trade name Avastin, Genentech/Roche) is the first clinically available angiogenesis inhibitor in the United States.
The humanized anti-VEGF-A monoclonal antibody fragment (Fab) Ranibizumab (trade name Lucentis, Genentech) is derived from the same parent mouse antibody as bevacizumab.
Both antibody drugs produce angiogenesis inhibition and slow the growth of new blood vessels.
Ranibizumab is much smaller than the parent complete antibody but shows stronger binding to VEGF-A after affinity maturation.
Ranibizumab can also be used to treat the "wet" type of age-related macular degeneration (AMD, also ARMD), a common form of age-related vision loss.
Vascular endothelial growth factor A (VEGF-A) stimulates angiogenesis in a variety of cancers, including colorectal, lung, breast, glioblastoma, kidney, and ovarian cancers.
Applications:Suitable for use in ELISA, Neutralization, Functional Assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by Ranibizumab.
Other applications not tested.
Recommended Dilution:Optimal dilutions to be determined by the researcher.
Storage and Stability:May be stored at 4℃ for short-term only.
Aliquot to avoid repeated freezing and thawing.
Store at -20℃.
Aliquots are stable for 12 months after receipt.
For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
